{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:14:08Z","timestamp":1793330048318,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["110-2314-B-002-123-MY3"],"award-info":[{"award-number":["110-2314-B-002-123-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["10-2314-B-002-123-MY3"],"award-info":[{"award-number":["10-2314-B-002-123-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["CMRO11403"],"award-info":[{"award-number":["CMRO11403"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["CMRO11303"],"award-info":[{"award-number":["CMRO11303"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["CMFHR113066"],"award-info":[{"award-number":["CMFHR113066"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1053\/j.ajkd.2024.11.013","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T13:08:20Z","timestamp":1737637700000},"page":"555-569.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials"],"prefix":"10.1053","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-7780","authenticated-orcid":false,"given":"Jui-Yi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuen-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1777-1181","authenticated-orcid":false,"given":"Jung-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Chih","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Fu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.ajkd.2024.11.013_bib1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.013_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"issue":"4S1","key":"10.1053\/j.ajkd.2024.11.013_bib3","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2024.01.001","article-title":"US Renal Data System 2023 annual data report: epidemiology of kidney disease in the United States","volume":"83","author":"Johansen","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1053\/j.ajkd.2024.11.013_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinternmed.2011.2230","article-title":"Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes","volume":"172","author":"Coca","year":"2012","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.013_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.amjmed.2014.07.042","article-title":"Multidisciplinary care program for advanced chronic kidney disease: reduces renal replacement and medical costs","volume":"128","author":"Chen","year":"2015","journal-title":"Am J Med"},{"issue":"5S","key":"10.1053\/j.ajkd.2024.11.013_bib6","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.013_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.11.013_bib8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1053\/j.ajkd.2024.11.013_bib9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.013_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.34067\/KID.0005852020","article-title":"Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis","volume":"2","author":"Tuttle","year":"2021","journal-title":"Kidney360"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.013_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1053\/j.ajkd.2024.11.013_bib12","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.11.013_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/dom.14601","article-title":"Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials","volume":"24","author":"Chaudhuri","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1053\/j.ajkd.2024.11.013_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000506634","article-title":"Diabetic kidney disease: challenges, advances, and opportunities","volume":"6","author":"Chen","year":"2020","journal-title":"Kidney Dis (Basel)"},{"issue":"10","key":"10.1053\/j.ajkd.2024.11.013_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4S","key":"10.1053\/j.ajkd.2024.11.013_bib16","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2024.11.013_bib17","first-page":"i145","article-title":"Kidney disease outcomes with semaglutide versus placebo across baseline KDIGO risk categories: a post hoc analysis of SUSTAIN 6 [60th ERA Congress, abstract 4441]","volume":"38","author":"Tuttle","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.013_bib18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12933-023-01949-7","article-title":"Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","volume":"22","author":"Rossing","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"10.1053\/j.ajkd.2024.11.013_bib19","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2024.11.013_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10193","key":"10.1053\/j.ajkd.2024.11.013_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ajkd.2024.11.013_bib22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2024.11.013_bib23","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2337\/dc23-0231","article-title":"Dulaglutide and kidney function-related outcomes in type 2 diabetes: a REWIND post hoc analysis","volume":"46","author":"Botros","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1053\/j.ajkd.2024.11.013_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2024.11.013_bib25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.11.013_bib26","article-title":"GLP-1 receptor agonists and kidney protection","volume":"55","author":"Greco","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.013_bib27","doi-asserted-by":"crossref","first-page":"F443","DOI":"10.1152\/ajprenal.00280.2019","article-title":"Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation","volume":"318","author":"Hviid","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.013_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2024.11.013_bib29","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2024.11.013_bib30","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2024.11.013_bib31","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, version 6.4 (updated August 2023)","article-title":"Chapter 8: Assessing risk of bias in a randomized trial","author":"Higgins","year":"2023"},{"issue":"4","key":"10.1053\/j.ajkd.2024.11.013_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A\u00a0new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"key":"10.1053\/j.ajkd.2024.11.013_bib33","volume":"vol 2023","author":"Ryan","year":"2016"},{"issue":"23","key":"10.1053\/j.ajkd.2024.11.013_bib34","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2024.11.013_bib35","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2024.11.013_bib36","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.013_bib37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ajkd.2024.11.013_bib38","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.013_bib39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1053\/j.ajkd.2024.11.013_bib40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.11.013_bib41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"10.1053\/j.ajkd.2024.11.013_bib42","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"issue":"25","key":"10.1053\/j.ajkd.2024.11.013_bib43","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1053\/j.ajkd.2024.11.013_bib44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10157","key":"10.1053\/j.ajkd.2024.11.013_bib45","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (HARMONY Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.013_bib46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","article-title":"Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial","volume":"28","author":"Ruff","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.11.013_bib47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00125-005-0128-9","article-title":"Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs","volume":"49","author":"Simonsen","year":"2006","journal-title":"Diabetologia"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.013_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurjpc\/zwaa081","article-title":"Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes","volume":"28","author":"Longato","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"13","key":"10.1053\/j.ajkd.2024.11.013_bib49","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10193","key":"10.1053\/j.ajkd.2024.11.013_bib50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2024.11.013_bib51","article-title":"The impact of glucagon-like peptide-1 receptor agonists on kidney outcomes: a meta-analysis of randomized placebo-controlled trials","author":"Mendon\u00e7a","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2024.11.013_bib52","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/dc20-1890","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1053\/j.ajkd.2024.11.013_bib53","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/dc19-2088","article-title":"Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study","volume":"43","author":"Pasternak","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.013_bib54","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.kint.2021.10.033","article-title":"GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes","volume":"101","author":"Xu","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.013_bib55","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12933-023-01793-9","article-title":"The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease","volume":"22","author":"Lin","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.ajkd.2024.11.013_bib56","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221112490","article-title":"The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice","volume":"13","author":"Von Scholten","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"18","key":"10.1053\/j.ajkd.2024.11.013_bib57","article-title":"Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"9","author":"Waijer","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"9","key":"10.1053\/j.ajkd.2024.11.013_bib58","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2024.11.013_bib59","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1053\/j.ajkd.2024.11.013_bib60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.2013.427","article-title":"The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential","volume":"85","author":"Fujita","year":"2014","journal-title":"Kidney Int"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2024.11.013_bib61","first-page":"i290","article-title":"Remodel: a mechanistic trial evaluating the effects of semaglutide on the kidneys in people with type 2 diabetes and chronic kidney disease [59th ERA Congress abstract MO399]","volume":"37","author":"Bjornstad","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2024.11.013_bib62","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.11.013_bib63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.2007.02890.x","article-title":"Effect of renal impairment on the pharmacokinetics of exenatide","volume":"64","author":"Linnebjerg","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.11.013_bib64","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4239\/wjd.v4.i5.190","article-title":"Effects of glucagon-like peptide-1 receptor agonists on renal function","volume":"4","author":"Filippatos","year":"2013","journal-title":"World J Diabetes"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.013_bib65","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.013_bib66","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12933-023-02035-8","article-title":"Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis","volume":"22","author":"Chen","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1053\/j.ajkd.2024.11.013_bib67","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/M13-2886","article-title":"Random-effects meta-analysis of inconsistent effects: a time for change","volume":"160","author":"Cornell","year":"2014","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1053\/j.ajkd.2024.11.013_bib68","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625000423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625000423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:27:06Z","timestamp":1777541226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625000423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0272638625000423"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.11.013","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}